Summit Global Investments Exelixis, Inc. Transaction History
Summit Global Investments
- $1.34 Billion
- Q1 2024
A detailed history of Summit Global Investments transactions in Exelixis, Inc. stock. As of the latest transaction made, Summit Global Investments holds 43,864 shares of EXEL stock, worth $985,624. This represents 0.08% of its overall portfolio holdings.
Number of Shares
43,864
Previous 38,458
14.06%
Holding current value
$985,624
Previous $923,000
12.78%
% of portfolio
0.08%
Previous 0.06%
Shares
9 transactions
Others Institutions Holding EXEL
# of Institutions
459Shares Held
246MCall Options Held
1.7MPut Options Held
1.02M-
Black Rock Inc. New York, NY34.9MShares$784 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA30.8MShares$693 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA26.7MShares$599 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.1MShares$339 Million0.56% of portfolio
-
State Street Corp Boston, MA13.1MShares$294 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $7.23B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...